The Betaseron plant in Emeryville, California is shutting down and outsourcing labor over a two year period. According to the San Francisco Business Times article I have referenced below, Betaseron/Betaferon produced 1.6 billion dollars in revenue in 2009 and thus, it does not make sense why they would be closing their factory in California only two years later.

This decision also comes in the same time period as GE getting FDA approval for their AngioViz Vascular Flow Analysis software, which produces images of vascular flow as well as:                    

1. Helps see where a blocked artery diminishes blood flow in the brain or other tissue;


2. Identifies the timing and amount of blood flow in abnormal vessel anatomy;


3. Observes flow in abnormal tissue before and after treatment to support interventional oncology treatment; and,


4. Visualizes peripheral artery blood flow before and after balloon angioplasty and stenting.

I believe the pharmaceutical industry is preparing to take a huge hit.

It is also noteworthy to mention that GE owns 49% of NBC, and now that they have produced a product that will directly profit off of diagnosing CCSVI in MS, we may see legitimate news coverage in the United States.

References:

1. San Francisco Business Times article dated May 26, 2011 entitled "Bayer Closing Emeryville Plant, Shedding 540 Jobs:"

http://www.bizjournals.com/sanfrancisco/news/2011/05/26/bayer-novartis-betaseron-ms.html

2. MedGadget article dated June 10, 2011 entitled "GE’s AngioViz Vascular Flow Analysis Software FDA OK’d:"

http://medgadget.com/2011/06/ges-angioviz-vascular-flow-analysis-software-fda-okd.html